Know Cancer

or
forgot password

The Diagnostic Technology Applied Research of CDK5RAP2 in Breast Cancer


N/A
N/A
N/A
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

The Diagnostic Technology Applied Research of CDK5RAP2 in Breast Cancer


The investigators selected 400 cases of women with primary breast cancer who were treated
with operation randomly,then detect the expression of CDK5RAP2 of cancer tissue. At the
same time randomly selected 100 women with primary breast cancer who were under neoadjuvant
chemotherapy. Detect the expression of CDK5RAP2 before and after neoadjuvant chemotherapy.


Inclusion Criteria:



1. Provision of informed consent

2. Pathological confirmation of breast cancer

3. Tumor stage(TNM):T2-4bN0-3M0

4. ER(+) and/or PR(+).

5. Premenopausal woman.

6. Age≥40 years

7. Measurable disease as per RECIST criteria

8. Karnofsky≥70

9. Laboratory criteria:

- PLT≥100*109/L

- WBC≥4000/mm3

- HGB≥10g/dl

- ALT and AST<2*ULN

Exclusion Criteria:

1. Presence of metastatic disease.

2. Inflammatory breast cancer.

3. Bilateral breast cancer.

4. previous chemotherapy or hormonal therapy for current breast neoplasm.

5. other malignant tumor (concurrent or previous).

6. Pregnant woman.

7. Hypersensitive to any drug in CEF regimen or any ingredient of Zoladex.

8. Any severe systemic disease contraindicating chemotherapy.

Type of Study:

Observational

Study Design:

Observational Model: Case Control, Time Perspective: Retrospective

Principal Investigator

Jin Zhang, Pro.

Investigator Role:

Study Chair

Investigator Affiliation:

TIANJIN CANCER HOSPITAL

Authority:

China: Ministry of Health

Study ID:

CIH-ZHJ-201205001

NCT ID:

NCT01634984

Start Date:

January 2012

Completion Date:

December 2013

Related Keywords:

  • Breast Cancer
  • expression of CDK5RAP2
  • Breast Neoplasms

Name

Location